Skip to main content
SpringerLink
Log in

Drug Treatment for Patients with Schizophrenia — A Balance of the Century

  • Conference paper
Search for the Causes of Schizophrenia

  • 129 Accesses

Abstract

Until the mid 20th century the pharmacological management of patients suffering from schizophrenia consisted exclusively of unspecific sedative measures. This situation changed dramatically with the advent of chlorpromazine which had been synthesized by chemists at Rhone-Poulenc in 1950. Originally found successful in manic patients, it was quickly realized that this drug was also very useful to treat agitated patients with schizophrenia and that its effect went way beyond mere sedation (Deniker 1988). After a number of scientific reports in the early 1950s, the term neuroleptic, signifying a “softening of the nervous system” was coined in 1955. The year before, Steck and Haase had independently described the “extrapyramidal and diencephalic syndrome” (Steck 1954) and the “psychomotor Parkinson syndrome” (Haase 1954), thereby recognizing a specific side effect profile of these new medications. In 1958 researchers at Janssen synthesized haloperidol (Niemegeers 1988), which was licensed in 1959. In the same year chlorprothixene, the first thioxanthene neuroleptic, was introduced by Lundbeck (Lassen 1988). The preclinical screening of clozapine started in 1960. Scientists at Dr. Wander AG suggested at first that this drug might be a strongly sedating analgesic (Stille and Fischer-Cornelssen 1988).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aitchison K., Kerwin R (1997) Cost-effectiveness of clozapine. Br J Psychiatry 171: 125–130

    Article  PubMed  CAS  Google Scholar 

  • Allison DB, Mentore JL, Heo M, Weiden P, Cappelleri J, Chandler LP (1998) Weight gain associated with conventional and newer antipsychotics: a meta-analysis. Eur Neuropsychopharmacol 8 (Suppl 2):S216-S217

    Article  Google Scholar 

  • Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P (1977) Agranulocytosis in patients treated with clozapine, a study of the Finnish epidemic. Acta Psychiatr Scand 56:241

    Article  PubMed  CAS  Google Scholar 

  • Andrews G T (1991) The cost of schizophrenia revisited. Schizophr Bull 17:389–394

    PubMed  CAS  Google Scholar 

  • Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group (1997) Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with Haloperidol and placebo. Biol Psychiatry 42:233–246

    Article  PubMed  CAS  Google Scholar 

  • Barnas C, Stuppäck C, Miller C, Haring C, Sperner-Unterweger B, Fleischhacker WW (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms: a double-blind trial vs. haloperidol. Int Clin Psychopharmacol 7:23–27

    Article  PubMed  CAS  Google Scholar 

  • Bäuml J, Kissling W, Buttner P, Pitschell-Walz G, Mayer C, Boerner R, Engel R, Peuker I, Welschehold M (1993) Informationszentrierte Patienten- und Angehörigengruppen zur Complianceverbesserung bei schizophrenen Psychosen. Verhaltenstherapie 3 (Suppl l):l-96

    Google Scholar 

  • Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996) Olanzapine versus placebo and haloperidol. Neuropsychopharmacology 14:111–123

    Article  PubMed  CAS  Google Scholar 

  • Bilder RM (1998) The neuropsychology of schizophrenia — what, when, where, how? In: Fleischhacker WW, Hinterhuber H, Meise U (eds) Schizophrene Störungen — State of the Art II, Verlag Integrative Psychiatrie, Innsbruck, pp 155–171

    Google Scholar 

  • Bond GR (1994) Applying psychiatric rehabilitation principles to employment: recent findings. In: Ancill RJ, Holliday S, Higenbottam J (eds) Schizophrenia: Exploring the Spectrum of Psychosis, John Wiley and Sons, Chichester, pp 49–65

    Google Scholar 

  • Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 155:499–504

    PubMed  CAS  Google Scholar 

  • Bunney GB, Bunney WE Jr, Carlsson A (1995) Schizophrenia and glutamate. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology — the fourth generation of progress. Raven Press, New York, pp 1205–1214

    Google Scholar 

  • Carpenter WT (1996) The treatment of negative symptoms: pharmacological and methodological issues. Br J Psychiatry 168 (Suppl 29):17–22

    Google Scholar 

  • Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, Hegerty J, Love R, Gounaris C, Zaremba S (1998) Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 155:914–920

    PubMed  CAS  Google Scholar 

  • Daniel DG, Wozniak P, Mack RJ, Mc Carthy BG, Sertindole Study Group (1998) Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 34:61–69

    PubMed  CAS  Google Scholar 

  • Deniker P (1988) Die Geschichte der Neuroleptika. In: Linde OK (ed) Pharmakopsychiatrie im Wandel der Zeit. Tilia Verlag, Klingenmünster, pp 119–133

    Google Scholar 

  • Fischer-Cornelssen KA, Ferner U, Steiner H (1974) Multifokale Psychopharmaka-Prüfung (multihospital trial). Arzneimittelforschung (Drug Research) 24:1706

    CAS  Google Scholar 

  • Fitton A, Heel R (1990) Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40:722–747

    Google Scholar 

  • Fleischhacker WW, Hummer M (1997) Drug treatment of schizophrenia in the 1990’s: achievements and future possibilities in optimising outcomes. Drugs 53:915–929

    Article  PubMed  CAS  Google Scholar 

  • Fleischhacker WW (1999) Treatment resistant schizophrenia: update and new approaches. Neuropsychobiology in press

    Google Scholar 

  • Gerlach J, Helweg E, Monrad A (1974) Clozapine and haloperidol in a single blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50:410

    Article  PubMed  CAS  Google Scholar 

  • Glazer WM, Jonstone BM (1997) Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 58 (Suppl 10):50–54

    PubMed  Google Scholar 

  • Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18: 296–304

    Article  PubMed  CAS  Google Scholar 

  • Green M, Marshall B, Wirshing W, Ames D, Marder S, Mc Gurk S, Kern RS, Mintz J (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154:799–804

    PubMed  CAS  Google Scholar 

  • Gross H, Langner E (1966) Das Wirkungsprofil eines chemisch neuartigen Breitband-Neuroleptikums der Dibenzodiazepingruppe. Wien Med Wochenschrift 116:614

    Google Scholar 

  • Gunasekara N, Spencer C (1999) Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs, in press

    Google Scholar 

  • Haase HJ (1954) Über Vorkommen und Deutung des psychomotorischen Parkinsonsyndroms bei Megaphen- bzw. Largactil-Dauerbehandlungen. Nervenarzt 25:486

    CAS  Google Scholar 

  • Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr (1998) Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 18:41–49

    Article  PubMed  CAS  Google Scholar 

  • Hirsch S, Link CG, Goldstein JM, Arvanitis LA (1996) Seroquel, a new atypical antipsychotic drug. Br J Psychiatry 168 (Suppl 29):45–56

    Google Scholar 

  • Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW (1999) Sexual disturbances during clozapine and haloperidol treatment. Am J Psychiatry 156:631–633

    PubMed  CAS  Google Scholar 

  • Jeste DV, Klausner M, Brecher M, Clyde C, Jones R, Arcs Study Group (1997) A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. Psychopharmacology 131:239–247

    Article  PubMed  CAS  Google Scholar 

  • Justin-Besancon L, Margarit J, Herrmann P (1988) Die Benzamide — Entdeckung und Entwicklung in der Psychiatric In: Linde OK (ed) Pharmakopsychiatrie im Wandel der Zeit, Tilia Verlag, Klingenmünster, pp 349–371

    Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H, The Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789–796

    Article  PubMed  CAS  Google Scholar 

  • Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR, Ziprasidone Study Group (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140:173–184

    Article  PubMed  CAS  Google Scholar 

  • Kleinberg DL, Davis JM, De Coster R, Van Baelen B, Brecher M (1999) Prolactin levels and adverse events in patients treated with rispierdone. J Clin Psychopharmacol 19:57–61

    Article  PubMed  CAS  Google Scholar 

  • Kolakowska T, Williams AO, Ardern M, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM (1985) Schizophrenia with good and poor outcome. I. Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 146:229–246

    Article  PubMed  CAS  Google Scholar 

  • Lassen N (1988) Die Geschichte der Thioxanthene. In: Linde OK (ed) Pharmakopsychiatrie im Wandel der Zeit. Tilia Verlag, Klingenmünster, pp 170–183

    Google Scholar 

  • Lemmens P, Brecher M, Van Baelen B (1999) A combined analysis of double-blind studies with risperidone versus placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 3:160–170

    Article  Google Scholar 

  • Liberman RP, Foy DW (1983) Psychiatric rehabilitation for chronic mental patients. Psychiat Ann 113:539–545

    Google Scholar 

  • Liddle PF, Barnes TRE, Curson DA, Patel M (1993) Depression and the experience of psychological deficits in schizophrenia. Acta Psychiatr Scand 88:243–247

    Article  PubMed  CAS  Google Scholar 

  • Linde OK (1992) Historischer Abriß: Geschichte der Psychopharmaka. In: Riederer P, Laux G, Pöldinger W (eds) Neuropsychopharmaka. Band 1, Springer, Berlin, pp 41–65

    Google Scholar 

  • Loo H., Poirier-Littre MF, Theron M, Reinh W, Fleurot O (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170:18–22

    Article  PubMed  CAS  Google Scholar 

  • Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825–835

    PubMed  CAS  Google Scholar 

  • Marder SR, Wirshing WC, Mintz J, et al (1996) Two-year outcome of social skills, training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry 153:1585–1592

    PubMed  CAS  Google Scholar 

  • Mari J, Streiner D (1996) Family Interventions for Schizophrenia: A Systematic Review. Cochrane Library. BMJ Publications, London

    Google Scholar 

  • Meltzer HY, Okayli G (1995) The reduction of suicidality during clozapine treatment in neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152:183–190

    PubMed  CAS  Google Scholar 

  • Möller HJ (1995) The negative component in schizophrenia. Acta Psychiatr Scand 91 (Suppl 388):11–14

    Article  Google Scholar 

  • Mortimer A (1997) Cognitive function in schizophrenia — do neuroleptics make a difference? Pharmacol Biochem Behav 56:789–795

    Article  PubMed  CAS  Google Scholar 

  • Niemegeers CJE (1988) Paul Janssen und die Entdeckung von Haloperidol und anderer Neuro-leptika. In: Linde OK (ed) Pharmakopsychiatrie im Wandel der Zeit. Tilia Verlag, Klingenmünster, pp 155–169

    Google Scholar 

  • Overall JE, Gorham DR (1962) Brief Psychiatric Rating Scale. Psychology Reports 10:779–812

    Google Scholar 

  • Owens MJ, Risch SC (1998) Atypical antipsychotics. In: Schatzberg AF, Nemeroff CB (eds) Textbook of Psychopharmacology, second edition. Am Psychiatric Press, Washington DC, pp 323–348

    Google Scholar 

  • Perlick D, Mattis S, Stasny P, Teresi J (1992) Neuropsychological discriminators of long-term inpatient or outpatient status in chronic schizophrenia. J Neuropsych Clin Neurosci 4:428–434

    CAS  Google Scholar 

  • Petit M, Raniwalla J, Tweed J, Leutenegger E, Dollfus S, Kelly F (1996) A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 32:81–87

    PubMed  CAS  Google Scholar 

  • Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166:712–726

    Article  PubMed  CAS  Google Scholar 

  • Prakash A, Lamb HM (1998) Zotepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 9:154–175

    Article  Google Scholar 

  • Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D (1997) A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New Eng J Med 337:809–815

    Article  PubMed  CAS  Google Scholar 

  • Roth B, Meltzer Y (1995) The role of serotonin in schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology — The Fourth Generation of Progress. Raven Press, New York, pp 1215–1227

    Google Scholar 

  • Rowley H, Kilpatrick I, Needham P, Heal D (1998) Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: an in vivo microdialysis study in freely moving rats. Neuropsychopharmacology 37:937–944

    CAS  Google Scholar 

  • Roy A (1986) Depression, attempted suicide, and suicide in patients with chronic schizophrenia. Br J Psychiatry 142:465–470

    Article  Google Scholar 

  • Schall U, Catts S, Chaturvedi S, Liebert B, Redenbach J, Karayanidis F, Ward P (1998) The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsycholoy and event-related potential measures. Int J Neuropsychopharmacol 1:19–29

    Article  PubMed  CAS  Google Scholar 

  • Schultz SC, Buckley PF (1995) Treatment-resistant schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia, Blackwell Science, pp 469–484

    Google Scholar 

  • Sharma T, Mockler D (1998) The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol 18 (Suppl 1):12S-19S

    PubMed  CAS  Google Scholar 

  • Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfmann-Etrog P, Modai I, Khaikin M, Weizman A (1997) Sulpride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychiatry 171:569–573

    Article  PubMed  CAS  Google Scholar 

  • Simpson GM, Angus JWS (1970) Drug induced extrapyramidal disorders. Acta Psychiatr Scand (Suppl 212)

    Google Scholar 

  • Siris SG (1995) Depression and schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Blackwell Science, Oxford, pp 128–145

    Google Scholar 

  • Steck H (1954) The extrapyramidal and diencephalic syndrome during treatment with Largactil and Serpasil. Ann Med Psychol (Paris) 112:737

    CAS  Google Scholar 

  • Stein LE, Test MA (1980) Alternative to mental hospital treatment I. Conceptual model, treatment program and clinical evaluation. Arch Gen Psychiatry 37:392–397

    Google Scholar 

  • Stille G, Fischer-Cornelssen K (1988) Die Entwicklung von Clozapin (Leponex) — ein Mysterium? In: Linde OK (ed) Pharmakopsychiatrie im Wandel der Zeit. Tilia Verlag, Klingenmünster, pp 333–348

    Google Scholar 

  • Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME (1997 a) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457–465

    PubMed  CAS  Google Scholar 

  • Tollefson GD, Sanger TM, Beasley CM (1997 b) Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trials with olanzapine. Am J Psychiatry 154:466–474

    PubMed  CAS  Google Scholar 

  • Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH (1997 c) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 154:1248–1254

    Google Scholar 

  • Tollefson GD, Sanger TM, Thieme ME (1998) Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 5:250–258

    Article  Google Scholar 

  • Van-Kammen D, McEvoy JP, Targum SD, Kardatzke D, Sebree T, Sertindole Study Group (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124:168–175

    Article  PubMed  CAS  Google Scholar 

  • Whitworth AB, Fleischhacker WW (1995) Adverse effects of antipsychotic drugs. Int Clin Psy-chopharmacol 9 (Suppl 5):21–27

    Article  Google Scholar 

  • Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak TJ, Sebree TB, Walling BA, Kashkin KB, Sertindole Study Group (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154:782–791

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biological Psychiatry, University of Innsbruck, Innsbruck, Austria

    W. W. Fleischhacker

Authors
  1. W. W. Fleischhacker
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Psychiatry Faculty of Medicine, University of São Paulo, P.O. Box 3671, 05403-010, São Paul, SP, Brazil

    Wagner F. Gattaz M.D. (Professor and Chairman) (Professor and Chairman)

  2. University of Heidelberg, Germany

    Heinz Häfner (Prof. em. of Psychiatry, Director em., Head) (Prof. em. of Psychiatry, Director em., Head)

  3. Central Institute of Mental Health, Germany

    Heinz Häfner (Prof. em. of Psychiatry, Director em., Head) (Prof. em. of Psychiatry, Director em., Head)

  4. Schizophrenia Research Unit, P.O.Box 122 120, 68072, Mannheim, Germany

    Heinz Häfner (Prof. em. of Psychiatry, Director em., Head) (Prof. em. of Psychiatry, Director em., Head)

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt

About this paper

Cite this paper

Fleischhacker, W.W. (1999). Drug Treatment for Patients with Schizophrenia — A Balance of the Century. In: Gattaz, W.F., Häfner, H. (eds) Search for the Causes of Schizophrenia. Steinkopff. https://doi.org/10.1007/978-3-642-47076-9_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-47076-9_24

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-642-47078-3

  • Online ISBN: 978-3-642-47076-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation